Global PCSK9 Inhibitors Market to 2030 – Insights, Epidemiology and Forecasts –


DUBLIN, November 04, 2021–(BUSINESS WIRE)–The “PCSK9 Inhibitors (PCSK9i) – Market Insights, Epidemiology, and Market Forecast – 2030” report has been added to ResearchAndMarkets.com’s offering.

This report delivers an in-depth understanding of PCSK9i, historical and forecasted epidemiology as well as the PCSK9 Inhibitors market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The PCSK9 Inhibitors market report provides disease areas, emerging drugs, PCSK9 Inhibitors market share of the individual therapies, current and forecasted PCSK9 Inhibitors market size from 2018 to 2030 segmented by seven major markets. The Report also covers current PCSK9 Inhibitors prescription eligibility criteria, approved and emerging therapies, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Key Findings

In the year 2020, the total prevalent cases of Familial Hypercholestrolemia was 3.1 million cases in the 7MM which are expected to grow during the study period, i.e., 2018-2030.

The disease epidemiology covered in the report provides historical as well as forecasted Von Hippel-Lindau disease epidemiology [segmented as Total prevalent cases of Familial Hypercholesterolemia, Total diagnosed cases of Familial Hypercholesterolemia, Total type-specific cases of Familial Hypercholesterolemia, Total age group-specific cases of Familial Hypercholesterolemia, Total mutation-specific cases of Familial Hypercholesterolemia, Total risk factor-specific cases of PCSK9 Inhibitors in Prophylactic/Preventive setting, and Total Treated cases of PCSK9 Inhibitors] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Companies Mentioned

Reasons to Buy

  • The report will help in developing business strategies by understanding trends shaping and driving the PCSK9 Inhibitors market.

  • To understand the future market competition in the PCSK9 Inhibitors market and Insightful review of the key market drivers and barriers.

  • Organize sales and marketing efforts by identifying the best opportunities for PCSK9 Inhibitors in the US, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.

  • Organize sales and marketing efforts by identifying the best opportunities for the PCSK9 Inhibitors market.

  • To understand the future market competition in PCSK9 Inhibitors market.

Key Topics Covered:

1. Key Insights

2. Report Introduction

3. PCSK9 Inhibitors Market Overview at a Glance

3.1. Market Share (%) Distribution of PCSK9 Inhibitors in 2018

3.2. Market Share (%) Distribution of PCSK9 Inhibitors in 2030

4. Executive Summary of PCSK9 Inhibitors (PCSK9i)

5. Key Events

5.1. Epidemiology and Market Methodology

6. PCSK9 Inhibitors (PCSK9i) Background and Overview

7. Introduction

7.1. PCSK9 gene biology

7.2. Functional mechanics of PCSK9

7.3. PCSK9 Inhibitors

7.4. PCSK9 Inhibition Strategies

7.5. The Approval Status of PCSK9 Inhibitors

7.6. Disease Areas of PCSK9 Inhibitors

7.6.1. Primary Hyperlipidemia

7.6.2. Prevention of Myocardial Infarction, Stroke, and Unstable Angina Requiring Hospitalization

8. Guidelines

8.1. ESC/EAS Guidelines for the Management of Dyslipidemias

8.2. American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

8.3. Recommendations From an Expert Panel of the National Lipid Association

8.4. Recommendations of the Spanish Society of Arteriosclerosis (SEA)

8.5. NICE guidelines

8.6. Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases

8.7. Comparison of guidelines

9. Epidemiology and Patient Population

9.1. Key Findings

9.2. Epidemiology of PCSK9 Inhibitors

9.3. Epidemiology Scenario

9.3.1. Total Prevalent Cases of Familial Hypercholestrolemia

9.3.2. Total Diagnosed Cases of Familial Hypercholesterolemia

9.3.3. Total Type-specific Cases of Familial Hypercholesterolemia

9.3.4. Total Age-specific Cases of Familial Hypercholesterolemia

9.3.5. Total Mutation-specific Cases of Familial Hypercholesterolemia

9.3.6. Total Risk factor-specific Cases of PCSK9 Inhibitors in Prophylactic/Preventive setting

9.3.7. Total Treated Cases of PCSK9 Inhibitors

10. Patient Journey

11. Key Endpoints in PCSK9 inhibitor Clinical Trials

12. Marketed Drugs

12.1. Praluent (Alirocumab): Sanofi/Regeneron Pharmaceuticals

12.1.1. Drug Description

12.1.2. Regulatory Milestones

12.1.3. Other Developmental Activities

12.1.4. Pivotal Clinical Trial

12.1.5. Ongoing Current Pipeline Activity

12.2. Repatha (Evolocumab/AMG 145): Amgen

12.2.1. Drug Description

12.2.2. Regulatory Milestones

12.2.3. Other Developmental Activities

12.2.4. Pivotal Clinical Trial

12.2.5. Ongoing Current Pipeline Activity

12.3. Leqvio (Inclisiran): Novartis/Alnylam Pharmaceuticals

12.3.1. Drug Description

12.3.2. Regulatory Milestones

12.3.3. Other Developmental Activities

12.3.4. Pivotal Clinical Trial

12.3.5. Ongoing Current Pipeline Activity

13. Emerging Therapies

13.1. LIB003 (Lerodalcibep): LIB Therapeutics

13.1.1. Drug Description

13.1.2. Clinical Development

13.1.3. Safety and Efficacy

13.2. AZD8233 (ION449): AstraZeneca and Ionis Pharmaceuticals

13.2.1. Drug Description

13.2.2. Other Developmental Activities

13.2.3. Clinical Development

13.2.4. Safety and Efficacy

13.3. Cepadacursen sodium (CIVI-007): CiVi Biopharma

13.3.1. Product Description

13.3.2. Other Developmental Activities

13.3.3. Clinical Development

13.3.4. Safety and Efficacy

14. PCSK9 inhibitors: 7 Major Market Analysis

14.1. Key Findings

14.2. Market Outlook

14.3. Market of PCSK9 Inhibitors (PCSK9i)

14.4. Market Size of PCSK9 inhibitors

14.4.1. Total Market Size of PCSK9 inhibitors

14.4.2. Market Size of PCSK9 inhibitors by Therapies (Treatment and Secondary Prevention)

15. Market Access and Reimbursement

16. KOL Views

17. Market Drivers

18. Market Barriers

19. SWOT Analysis

20. Unmet Needs

21. Appendix

22. Publisher Capabilities

23. Disclaimer

24. About the Publisher

For more information about this report visit https://www.researchandmarkets.com/r/e4bc6x

View source version on businesswire.com: https://www.businesswire.com/news/home/20211104006091/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900



Read More: Global PCSK9 Inhibitors Market to 2030 – Insights, Epidemiology and Forecasts –

You might also like